FDA schedules advisory committee hearing for Lynparza prostate cancer application
What once appeared to be a slam dunk for Merck and AstraZeneca’s PARP inhibitor Lynparza may no longer be a sure thing.
The FDA will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
